PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Class Ia Phosphatidylinositol 3-Kinase
  • Lymphoma, Non-Hodgkin
  • Purines
  • Quinazolinones

abstract

  • In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov number, NCT01282424.).

publication date

  • March 17, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4039496

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1314583

PubMed ID

  • 24450858

Additional Document Info

start page

  • 1008

end page

  • 18

volume

  • 370

number

  • 11